Author:
Xue Tongchun,Le Fan,Chen Rongxin,Xie Xiaoying,Zhang Lan,Ge Ningling,Chen Yi,Wang Yanhong,Zhang Boheng,Ye Shenglong,Ren Zhenggang
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Hematology,General Medicine
Reference27 articles.
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Earl TM, Chapman WC. Tumor size remains key for prediction of hepatocellular carcinoma recurrence after liver transplantation. Ann Surg Oncol. 2011;18:1217–8.
3. Kim SJ, Lee KK, Kim DG. Tumor size predicts the biological behavior and influence of operative modalities in hepatocellular carcinoma. Hepatogastroenterology. 2010;57:121–6.
4. Jin YJ, Lee JW, Choi YJ, Chung HJ, Kim YS, Lee KY et al. Surgery versus transarterial chemoembolization for solitary large hepatocellular carcinoma of BCLC stage A. J Gastrointest Surg. 2014;18:555–61.
5. Liang HY, Lu LG, Hu BS, Li Y, Shao PJ. Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas. Chin Med J (Engl). 2013;126:4270–6.